Genmab's HuMax-CD4 Displays Unique Mechanism of Action

Summary:  Genmab announces unique mechanisms of action of HuMax-CD4             
(zanolimumab).                                                                  

Copenhagen, Denmark; October 15, 2007 - Genmab A/S (OMX: GEN) announced today   
the discovery of unique mechanisms of action of HuMax-CD4(R) (zanolimumab),     
currently in development for treatment of cutaneous T-cell lymphoma and         
non-cutaneous T-cell lymphoma.                                                  

In experimental laboratory models and studies in human patients, HuMax-CD4      
eliminated CD4 positive T-cells by combining rapid signaling inhibition with    
efficient engagement of immune system killer cells.  The signaling in CD4       
positive target cells is inhibited through a combination of both potent         
inhibition of signaling via the T cell receptor, and the activation of different
signaling proteins that can effectively stop cell signaling processes. Blockade 
of cell signaling is a key feature for effective antibody therapeutics for      
cancer. CD4 positive T-cells are also attacked by immune effector cells via an  
immune defense mechanism called antibody-dependent cell-mediated cytotoxicity   
(ADCC).  HuMax-CD4, furthermore, induces the down-modulation of CD4 targets from
target cell surfaces via a slow immune cell-mediated mechanism.                 

This data will be published today in an article in the journal Cancer Research. 

“These exciting data document the way HuMax-CD4 works to kill target cells and  
highlights its potential for the treatment of cancer,” said Prof. Jan G.J. van  
de Winkel, Chief Scientific Officer of Genmab.
                                  
About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
and UniBody(R) are all trademarks of Genmab A/S.                                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Investor News No. 13/2007                                                       

###